1
|
Schmalz F, Fischer J, Innes H, Buch S, Möller C, Matz-Soja M, von Schönfels W, Krämer B, Langhans B, Klüners A, Soyka M, Stickel F, Nattermann J, Strassburg CP, Berg T, Lutz P, Nischalke HD. High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. JHEP Rep 2023; 5:100684. [PMID: 36879887 PMCID: PMC9985032 DOI: 10.1016/j.jhepr.2023.100684] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 01/11/2023] [Accepted: 01/14/2023] [Indexed: 01/26/2023] Open
Abstract
Background & Aims Progression of alcohol-associated liver disease (ALD) is driven by genetic predisposition. The rs13702 variant in the lipoprotein lipase (LPL) gene is linked to non-alcoholic fatty liver disease. We aimed at clarifying its role in ALD. Methods Patients with alcohol-associated cirrhosis, with (n = 385) and without hepatocellular carcinoma (HCC) (n = 656), with HCC attributable to viral hepatitis C (n = 280), controls with alcohol abuse without liver damage (n = 366), and healthy controls (n = 277) were genotyped regarding the LPL rs13702 polymorphism. Furthermore, the UK Biobank cohort was analysed. LPL expression was investigated in human liver specimens and in liver cell lines. Results Frequency of the LPL rs13702 CC genotype was lower in ALD with HCC in comparison to ALD without HCC both in the initial (3.9% vs. 9.3%) and the validation cohort (4.7% vs. 9.5%; p <0.05 each) and compared with patients with viral HCC (11.4%), alcohol misuse without cirrhosis (8.7%), or healthy controls (9.0%). This protective effect (odds ratio [OR] = 0.5) was confirmed in multivariate analysis including age (OR = 1.1/year), male sex (OR = 3.0), diabetes (OR = 1.8), and carriage of the PNPLA3 I148M risk variant (OR = 2.0). In the UK Biobank cohort, the LPL rs13702 C allele was replicated as a risk factor for HCC. Liver expression of LPL mRNA was dependent on LPL rs13702 genotype and significantly higher in patients with ALD cirrhosis compared with controls and alcohol-associated HCC. Although hepatocyte cell lines showed negligible LPL protein expression, hepatic stellate cells and liver sinusoidal endothelial cells expressed LPL. Conclusions LPL is upregulated in the liver of patients with alcohol-associated cirrhosis. The LPL rs13702 high producer variant confers protection against HCC in ALD, which might help to stratify people for HCC risk. Impact and implications Hepatocellular carcinoma is a severe complication of liver cirrhosis influenced by genetic predisposition. We found that a genetic variant in the gene encoding lipoprotein lipase reduces the risk for hepatocellular carcinoma in alcohol-associated cirrhosis. This genetic variation may directly affect the liver, because, unlike in healthy adult liver, lipoprotein lipase is produced from liver cells in alcohol-associated cirrhosis.
Collapse
Key Words
- ALD, alcohol-associated liver disease
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- Alcohol-associated liver disease
- BCLC, Barcelona Clinic Liver Cancer
- BSA, bovine serum albumin
- Cirrhosis
- FCS, foetal calf serum
- FIB-4, fibrosis 4
- GADPH, glyceraldehyde 3-phosphate dehydrogenase
- GGT, gamma-glutamyl transferase
- HCC
- HCC, hepatocellular carcinoma
- HSCs, hepatic stellate cells
- HbA1c, glycated haemoglobin
- LPL
- LPL, lipoprotein lipase
- LSECs, liver sinusoidal endothelial cells
- MAF, minor allele frequency
- NAFLD, non-alcoholic fatty liver disease
- NASH, non-alcoholic steatohepatitis
- OR, odds ratio
- PNPLA3, patatin-like phospholipase domain-containing protein 3
- T2DM, type 2 diabetes mellitus
- UKB, UK Biobank
- rs13702
- rs328
Collapse
Affiliation(s)
- Franziska Schmalz
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | - Janett Fischer
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
| | - Hamish Innes
- School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
| | - Stephan Buch
- Medical Department 1, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
| | - Christine Möller
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | - Madlen Matz-Soja
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
| | - Witigo von Schönfels
- Department of General, Visceral-, Thoracic-, Transplantation- and Pediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, and Christian-Albrecht University (CAU), Kiel, Germany
| | - Benjamin Krämer
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | - Bettina Langhans
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | - Alexandra Klüners
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | - Michael Soyka
- Psychiatric Hospital, Ludwig Maximilians University, Munich, Germany
| | - Felix Stickel
- Department of Gastroenterology and Hepatology, University Hospital of Zürich, Switzerland
| | - Jacob Nattermann
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | | | - Thomas Berg
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
| | - Philipp Lutz
- Department of Internal Medicine I, University Hospital, University of Bonn, Germany
| | | |
Collapse
|
2
|
Kessler T, Schunkert H. Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies. JACC Basic Transl Sci 2021; 6:610-623. [PMID: 34368511 PMCID: PMC8326228 DOI: 10.1016/j.jacbts.2021.04.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/04/2021] [Accepted: 04/01/2021] [Indexed: 12/12/2022]
Abstract
Many cardiovascular diseases are facilitated by strong inheritance. For example, large-scale genetic studies identified hundreds of genomic loci that affect the risk of coronary artery disease. At each of these loci, common variants are associated with disease risk with robust statistical evidence but individually small effect sizes. Only a minority of candidate genes found at these loci are involved in the pathophysiology of traditional risk factors, but experimental research is making progress in identifying novel, and, in part, unexpected mechanisms. Targets identified by genome-wide association studies have already led to the development of novel treatments, specifically in lipid metabolism. This review summarizes recent genetic and experimental findings in this field. In addition, the development and possible clinical usefulness of polygenic risk scores in risk prediction and individualization of treatment, particularly in lipid metabolism, are discussed.
Collapse
Affiliation(s)
- Thorsten Kessler
- German Heart Centre Munich, Department of Cardiology, Technical University of Munich, Munich, Germany.,German Centre for Cardiovascular Research (DZHK e.V.), partner site Munich Heart Alliance, Munich, Germany
| | - Heribert Schunkert
- German Heart Centre Munich, Department of Cardiology, Technical University of Munich, Munich, Germany.,German Centre for Cardiovascular Research (DZHK e.V.), partner site Munich Heart Alliance, Munich, Germany
| |
Collapse
|
3
|
Yoon SJ, Kim SK, Lee NY, Choi YR, Kim HS, Gupta H, Youn GS, Sung H, Shin MJ, Suk KT. Effect of Korean Red Ginseng on metabolic syndrome. J Ginseng Res 2020; 45:380-389. [PMID: 34025131 PMCID: PMC8134847 DOI: 10.1016/j.jgr.2020.11.002] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 09/24/2020] [Accepted: 11/02/2020] [Indexed: 12/27/2022] Open
Abstract
Metabolic syndrome (MS) refers to a clustering of at least three of the following medical conditions: high blood pressure, abdominal obesity, hyperglycemia, low high-density lipoprotein level, and high serum triglycerides. MS is related to a wide range of diseases which includes obesity, diabetes, insulin resistance, cardiovascular disease, dyslipidemia, or non-alcoholic fatty liver disease. There remains an ongoing need for improved treatment strategies for MS. The most important risk factors are dietary pattern, genetics, old age, lack of exercise, disrupted biology, medication usage, and excessive alcohol consumption, but pathophysiology of MS has not been completely identified. Korean Red Ginseng (KRG) refers to steamed/dried ginseng, traditionally associated with beneficial effects such as anti-inflammation, anti-fatigue, anti-obesity, anti-oxidant, and anti-cancer effects. KRG has been often used in traditional medicine to treat multiple metabolic conditions. This paper summarizes the effects of KRG in MS and related diseases such as obesity, cardiovascular disease, insulin resistance, diabetes, dyslipidemia, or non-alcoholic fatty liver disease based on experimental research and clinical studies.
Collapse
Key Words
- ACC, Acetyl-Coenzyme A carboxylase
- ADP, adenosine diphosphate
- AG, American ginseng extract
- AGE, advanced glycation end product
- ALT, alanine aminotransferase
- AMPK, AMP-activated protein kinase
- AST, aspartate aminotransferase
- Akt, protein kinase B
- BMI, body mass index
- C/EBPα, CCAAT/enhancer-binding protein alpha
- COX-2, cyclooxygenase-2
- CPT, current perception threshold
- CPT-1, carnitine palmitoyl transferase 1
- CRP, C-reactive protein
- CVD, Cardiovascular disease
- DBP, diastolic blood pressure
- DEN, diethyl nitrosamine
- EAT, epididymis adipose tissue
- EF, ejection fraction
- FABP4, fatty acid binding protein 4
- FAS, Fatty acid synthase
- FFA, free fatty acid
- FR, fine root concentration
- FS, fractional shortening
- GBHT, ginseng-plus-Bai-Hu-Tang
- GLUT, glucose transporter type
- GPx, glutathione peroxidase
- GS, ginsenoside
- GST, glutathione S-transferase
- GST-P, glutathione S-transferase placental form
- GTT, glucose tolerance test
- HCC, hepatocellular carcinoma
- HCEF-RG, hypotensive components-enriched fraction of red ginseng
- HDL, high-density lipoprotein
- HFD, High fat diet
- HOMA-IR, homeostasis model assessment of insulin resistance index
- HbA1c, glycosylated hemoglobin
- I.P., intraperitoneal injection
- IL, interleukin
- IR, insulin resistance
- ITT, insulin tolerance test
- Insulin resistance
- KRG, Korean Red Ginseng
- LDL, low-density lipoprotein
- LPL, lipoprotein lipase
- Lex, lower extremities
- MDA, malondialdehyde
- MMP, Matrix metallopeptidases
- MS, Metabolic syndrome
- Metabolic syndrome
- NAFLD, Non-alcoholic fatty liver disease
- NF-кB, nuclear factor kappa-light-chain-enhancer of activated B cells
- NK cell, Natural killer cell
- NMDA-NR1, N-methyl-D-aspartate NR1
- NO, nitric oxide
- NRF1, Nuclear respiratory factor 1
- Non-alcoholic fatty liver disease
- Nrf2, Nuclear factor erythroid 2-related factor 2
- OLETF rat, Otsuka Long-Evans Tokushima fatty rat
- PCG-1α, PPAR-γ coactivator-1α
- PI3K, phosphoinositide 3-kinase
- PPAR, peroxisome proliferator-activated receptors
- PPD, protopanaxadiol
- PPT, protopanaxatriol
- Panax ginseng
- REKRG, Rg3-enriched KRG
- ROS, Reactive oxygen species
- Rg3-KGE, Rg3-enriched KRG extract
- SBP, systolic blood pressure
- SCD, Stearoyl-Coenzyme A desaturase
- SHR, spontaneously hypertensive rat
- SREBP-1C, Sterol regulatory element-binding protein 1
- STAT5, Signal transducer and activator of transcription 5
- STZ, streptozotocin
- TBARS, thiobarbituric acid reactive substances
- TC, total cholesterol
- TG, triglyceride
- TNF, tumor necrosis factor
- UCP, Mitochondrial uncoupling proteins
- VLDL, very low-density lipoprotein
- iNOS, inducible nitric oxide synthase
- t-BHP, tert-butyl hyperoxide
- tGST, total glutathione
Collapse
Affiliation(s)
- Sang Jun Yoon
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Seul Ki Kim
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Na Young Lee
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Ye Rin Choi
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Hyeong Seob Kim
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Haripriya Gupta
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Gi Soo Youn
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Hotaik Sung
- School of Medicine, Kyungpook National University, Daegu, Republic of Korea
| | - Min Jea Shin
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| | - Ki Tae Suk
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, Republic of Korea
| |
Collapse
|
4
|
Ścibior A, Pietrzyk Ł, Plewa Z, Skiba A. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends. J Trace Elem Med Biol 2020; 61:126508. [PMID: 32305626 PMCID: PMC7152879 DOI: 10.1016/j.jtemb.2020.126508] [Citation(s) in RCA: 80] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 02/25/2020] [Accepted: 03/19/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND Vanadium (V) is an element with a wide range of effects on the mammalian organism. The ability of this metal to form organometallic compounds has contributed to the increase in the number of studies on the multidirectional biological activity of its various organic complexes in view of their application in medicine. OBJECTIVE This review aims at summarizing the current state of knowledge of the pharmacological potential of V and the mechanisms underlying its anti-viral, anti-bacterial, anti-parasitic, anti-fungal, anti-cancer, anti-diabetic, anti-hypercholesterolemic, cardioprotective, and neuroprotective activity as well as the mechanisms of appetite regulation related to the possibility of using this element in the treatment of obesity. The toxicological potential of V and the mechanisms of its toxic action, which have not been sufficiently recognized yet, as well as key information about the essentiality of this metal, its physiological role, and metabolism with certain aspects on the timeline is collected as well. The report also aims to review the use of V in the implantology and industrial sectors emphasizing the human health hazard as well as collect data on the directions of further research on V and its interactions with Mg along with their character. RESULTS AND CONCLUSIONS Multidirectional studies on V have shown that further analyses are still required for this element to be used as a metallodrug in the fight against certain life-threatening diseases. Studies on interactions of V with Mg, which showed that both elements are able to modulate the response in an interactive manner are needed as well, as the results of such investigations may help not only in recognizing new markers of V toxicity and clarify the underlying interactive mechanism between them, thus improving the medical application of the metals against modern-age diseases, but also they may help in development of principles of effective protection of humans against environmental/occupational V exposure.
Collapse
Key Words
- 3-HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA
- AIDS, acquired immune deficiency syndrome
- ALB, albumin
- ALP, alkaline phosphatase
- AS, antioxidant status
- Akt, protein kinase B (PKB)
- AmD, Assoc American Dietetic Association
- Anti-B, anti-bacterial
- Anti-C, anti-cancer
- Anti-D, anti-diabetic
- Anti-F, anti-fungal
- Anti-O, anti-obesity
- Anti-P, anti-parasitic
- Anti-V, anti-viral
- Anti−HC, anti-hypercholesterolemic
- ApoA-I, apolipoprotein A
- ApoB, apolipoprotein B
- B, bone
- BCOV, bis(curcumino)oxavanadyl
- BEOV, bis(ethylmaltolato)oxovanadium
- BMOV, bis(maltolato)oxavanadium(IV)
- Bim, Blc-2 interacting mediator of cell death
- Biological role
- BrOP, bromoperoxidase
- C, cholesterol
- C/EBPα, CCAAT-enhancer-binding protein α
- CD4, CD4 receptor
- CH, cerebral hemisphere
- CHO-K1, Chinese hamster ovary cells
- CXCR-4, CXCR-4 chemokine co-receptor
- Cardio-P, cardioprotective
- Citrate-T, citrate transporter
- CoA, coenzyme A
- Cyt c, cytochrome c
- DM, diabetes mellitus
- ELI, extra low interstitial
- ERK, extracellular regulated kinase
- FHR, fructose hypertensive rats
- FKHR/FKHR1/AFX, class O members of the forkhead transcription factor family
- FLIP, FLICE-inhibitory protein
- FOXOs, forkhead box class O family member proteins
- FPP, farnesyl-pyrophosphate
- FasL, Fas ligand, FER: ferritin
- GI, gastrointestinal
- GLU, glucose
- GLUT-4, glucose transporter type 4
- GPP, geranyl-pyrophosphate
- GPT, glutamate-pyruvate transaminase
- GR, glutathione reductase
- GSH, reduced glutathione
- GSSG, disulfide glutathione
- HDL, high-density lipoproteins
- HDL-C, HDL cholesterol
- HIV, human immunodeficiency virus
- HMMF, high molecular mass fraction
- HOMA-IR, insulin resistance index
- Hb, hemoglobin
- HbF, hemoglobin fraction
- Hyper-LEP, hyperleptynemia
- IDDM, insulin-dependent diabetes mellitus
- IGF-IR, insulin-like growth factor receptor
- IL, interleukin
- INS, insulin
- INS-R, insulin resistance
- INS-S, insulin sensitivity
- IPP, isopentenyl-5-pyrophosphate
- IRS, insulin receptor tyrosine kinase substrate
- IgG, immunoglobulin G
- Industrial importance
- Interactions
- JAK2, Janus kinase 2
- K, kidney
- L, liver
- L-AA, L-ascorbic acid
- LDL, low-density lipoproteins
- LDL-C, LDL cholesterol
- LEP, leptin
- LEP-R, leptin resistance
- LEP-S, leptin sensitivity
- LEPS, the concentration of leptin in the serum
- LMMF, low molecular mass fraction
- LPL, lipoprotein lipase
- LPO, lipid peroxidation
- Lactate-T, lactate transporter
- M, mitochondrion
- MEK, ERK kinase activator
- MRC, mitochondrial respiratory chain
- NAC, N-acetylcysteine
- NEP, neutral endopeptidase
- NIDDM, noninsulin-dependent diabetes mellitus
- NO, nitric oxide
- NPY, neuropeptide Y
- NaVO3, sodium metavanadate
- Neuro-P, neuroprotective
- OXPHOS, oxidative phosphorylation
- Organic-AT, organic anion transporter
- Over-W, over-weight
- P, plasma
- PANC-1, pancreatic ductal adenocarcinoma cells
- PARP, poly (ADP-ribose) polymerase
- PLGA, (Poly)Lactide-co-Glycolide copolymer
- PO43−, phosphate ion
- PPARγ, peroxisome-activated receptor γ
- PTK, tyrosine protein kinase
- PTP, protein tyrosine phosphatase
- PTP-1B, protein tyrosine phosphatase 1B
- Pharmacological activity
- Pi3K, phosphoinositide 3-kinase (phosphatidylinositol 3-kinase)
- RBC, erythrocytes
- ROS, reactive oxygen species
- RT, reverse transcriptase
- SARS, severe acute respiratory syndrome
- SAcP, acid phosphatase secreted by Leshmania
- SC-Ti-6Al-4V, surface-coated Ti-6Al-4V
- SHR, spontaneously hypertensive rats
- SOD, superoxide dismutase
- STAT3, signal transducer/activator of transcription 3
- Sa, mean roughness
- Sq, root mean square roughness
- Sz, ten-point height
- TC, total cholesterol
- TG, triglycerides
- TS, transferrin saturation
- Tf, transferrin
- TfF, transferrin fraction
- TiO2, nHA:Ag-Ti-6Al-4V: titanium oxide-based coating containing hydroxyapatite nanoparticle and silver particles
- Top-IB, IB type topoisomerase
- Toxicological potential
- V, vanadium
- V-BrPO, vanadium bromoperoxidase
- V-DLC, diamond-like layer with vanadium
- V5+/V4+, pentavalent/tetravalent vanadium
- VO2+, vanadyl cation
- VO2+-FER, vanadyl-ferritin complex
- VO4-/VO3-, vanadate anion
- VO43-, vanadate ion
- VS, vanadyl sulfate
- Vanadium
- WB, whole blood
- ZDF rats, Zucker diabetic fatty rats
- ZF rats, Zucker fatty rats
- breakD, breakdown
- eNOS, endothelial nitric oxide synthase
- mo, months
- n-HA, nano-hydroxyapatite
- pRb, retinoblastoma protein
- wk, weeks
Collapse
Affiliation(s)
- Agnieszka Ścibior
- Laboratory of Oxidative Stress, Centre for Interdisciplinary Research, The John Paull II Catholic University of Lublin, Poland
| | - Łukasz Pietrzyk
- Laboratory of Oxidative Stress, Centre for Interdisciplinary Research, The John Paull II Catholic University of Lublin, Poland
- Department of Didactics and Medical Simulation, Chair of Anatomy, Medical University of Lublin, Poland
| | - Zbigniew Plewa
- Department of General, Oncological, and Minimally Invasive Surgery, 1 Military Clinical Hospital with the Outpatient Clinic in Lublin, Poland
| | - Andrzej Skiba
- Military Clinical Hospital with the Outpatient Clinic in Lublin, Poland
| |
Collapse
|
5
|
Abstract
Since elevated plasma triglycerides are an independent risk factor for cardiovascular diseases, lipoprotein lipase (LPL) is an interesting target for drug development. However, investigation of LPL remains challenging, as most of the commercially available assays are limited to the determination of LPL activity. Thus, we focused on the evaluation of a simple in vitro real-time fluorescence assay for the measurement of LPL activity that can be combined with additional cell or molecular biological assays in the same cell sample. Our procedure allows for a more comprehensive characterization of potential regulatory compounds targeting the LPL system. The presented assay procedure provides several advantages over currently available commercial in vitro LPL activity assays:12-well cell culture plate design for the simultaneous investigation of up to three different compounds of interest (including all assay controls). 24 h real-time acquisition of LPL activity for the identification of the optimal time point for further measurements. Measurement of LPL activity can be supplemented by additional cell or molecular biological assays in the same cell sample.
Collapse
Key Words
- ANGPTL, angiopoietin-like
- FBS, fetal bovine serum
- FFA, free fatty acid
- FI, fluorescence intensity
- Fluorescence
- LPL activity assay
- LPL, lipoprotein lipase
- Lipoprotein lipase (LPL)
- MTT, methylthiazolyldiphenyl-tetrazolium bromide
- PBS, phosphate-buffered saline
- PPAR, proliferator-activated receptor
- PSG, L‐glutamine-penicillin-streptomycin
- RFU, relative fluorescence units
- Real-time assay
- VLDL, very low-density lipoprotein
Collapse
Affiliation(s)
- Stefan Kluge
- Institute of Nutritional Sciences, Friedrich Schiller University Jena, Germany.,Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany
| | - Lisa Boermel
- Institute of Nutritional Sciences, Friedrich Schiller University Jena, Germany.,Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany
| | - Martin Schubert
- Institute of Nutritional Sciences, Friedrich Schiller University Jena, Germany.,Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany
| | - Stefan Lorkowski
- Institute of Nutritional Sciences, Friedrich Schiller University Jena, Germany.,Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig, Germany
| |
Collapse
|
6
|
Kakutani H, Yuzuriha T, Akiyama E, Nakao T, Ohta S. Complex toxicity as disruption of adipocyte or osteoblast differentiation in human mesenchymal stem cells under the mixed condition of TBBPA and TCDD. Toxicol Rep 2018; 5:737-743. [PMID: 29928592 PMCID: PMC6008500 DOI: 10.1016/j.toxrep.2018.06.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 05/04/2018] [Accepted: 06/11/2018] [Indexed: 11/18/2022] Open
Abstract
People are frequently and unintentionally exposed to many chemical compounds, such as environmental pollutants and endocrine-disrupting chemicals (EDCs), in food and from the atmosphere. In particular, endocrine-disrupting TBBPA and dioxins are found in human breast milk and in the body. Conventional studies evaluate toxicity by administering a single substance to cells or animals, but evaluation of the toxicity of mixtures of these ingested compounds is essential for “true” toxicological assessment. We evaluated toxic effects in vitro using human mesenchymal stem cells (hMSCs). TBBPA increased the number of lipid droplets, and upregulated the expression of adipocyte-related mRNA, aP2 and LPL, through a PPARγ-dependent mechanism. TCDD suppressed lipid droplets and adipocyte-related mRNA levels. Adipocyte differentiation was stimulated by TBBPA and inhibited by TCDD in a dose-dependent manner. TBBPA did not influence osteoblast differentiation, but TCDD suppressed ALP staining and activity, calcium deposition, and osteoblast-related mRNA levels. In a mixture of TBBPA and TCDD, TBBPA inhibited TCDD suppression of adipocyte and osteoblast differentiation in a dose-dependent manner. Interestingly, we observed lipid droplets in TBBPA-treated cells differentiated into osteoblasts. These results suggest that TBBPA and TCDD disrupted differentiation into adipocytes and osteoblasts and contributes to a more complete toxicological understanding of exposure to these chemical substances.
Collapse
Key Words
- 2,3,7,8-tetrachlorodibenzo-p-dioxin
- ALP, alkaline phosphatase
- Adipocyte differentiation
- BFRs, brominated flame retardants
- C/EBPα, CCAAT-enhancer-binding protein alpha
- DOHaD, developmental origins of health and disease
- EDCs, endocrine-disrupting chemicals
- Human mesenchymal stem cell
- LPL, lipoprotein lipase
- MSC, mesenchymal stem cell
- Osteoblast differentiation
- PCDDs/DFs, polychlorinated dibenzo-p-dioxins and dibenzofurans
- PPARγ, peroxisome proliferator activated receptor gamma
- RUNX2, runt-related transcription factor 2
- TBBPA, tetrabromobisphenol A
- TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin
- Tetrabromobisphenol A
- aP2, adipocyte-specific protein 2
Collapse
Affiliation(s)
- Hideki Kakutani
- Laboratory of Disease Prevention, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Tomohiro Yuzuriha
- Laboratory of Disease Prevention, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Ema Akiyama
- Laboratory of Disease Prevention, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Teruyuki Nakao
- Laboratory of Disease Prevention, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Souichi Ohta
- Laboratory of Disease Prevention, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| |
Collapse
|
7
|
Lee HJ, Le B, Lee DR, Choi BK, Yang SH. Cissus quadrangularis extract (CQR-300) inhibits lipid accumulation by downregulating adipogenesis and lipogenesis in 3T3-L1 cells. Toxicol Rep 2018; 5:608-614. [PMID: 29854631 PMCID: PMC5977379 DOI: 10.1016/j.toxrep.2018.02.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Revised: 02/09/2018] [Accepted: 02/27/2018] [Indexed: 02/03/2023] Open
Abstract
CQR-300 inhibited lipid accumulation in 3T3-L1 adipocytes. CQR-300 inhibited the differentiation of adipocytes by regulating adipogenesis. CQR-300 reduced fatty acids and triglyceride accumulation via downregulating lipogenesis.
The objective of this study was to evaluate the anti-obesity activity and the action mechanism of Cissus quadrangularis extracts (CQR-300) in 3T3-L1 adipocytes. Cissus quadrangularis was extracted with hot water, resulting in CQR-300. The anti-obesity activity of CQR-300 in 3T3-L1 adipocytes was examined by Oil-red O staining. Possible mechanisms of CQR-300 in 3T3-L1 adipocytes were determined by real-time PCR and western blot. Treatment with CQR-300 inhibited lipid accumulation without showing cytotoxicity to 3T3-L1 adipocytes. Furthermore, CQR-300 decreased adipogenesis/lipogenesis-related mRNA expression levels of fatty acid binding protein (aP2), fatty acid synthase (FAS), lipoprotein lipase (LPL), stearoyl-CoA desaturase-1 (SCD-1), and acetyl-CoA carboxylase (ACC). CQR-300 also down-regulated expression levels of adipogenesis/lipogenesis-associated proteins, including peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα), sterol regulatory element binding protein-1c (SREBP-1c), and FAS. It’s also up-regulated the expression level of phosphorylated-AMPK (p-AMPK). Collectively, these results suggested that CQR-300 might have an anti-obesity effect by its ability to decrease expression levels of adipogenesis/lipogenesis-related genes and proteins.
Collapse
Key Words
- ACC, acetyl-CoA carboxylase
- AMPK, AMP-activated protein kinase
- Adipocytes
- Adipogenesis
- Anti-obesity
- BCS, bovine calf serum
- C/EBPα, CCAAT/enhancer-binding protein α
- CQR-300, Cissus quadrangularis extract
- Cissus quadrangularis extract (CQR-300)
- DMEM, Dulbecco’s modified Eagle’s medium
- FAS, fatty acid synthase
- FAS-α, fatty-acid synthase
- FBS, fetal bovine serum
- GAPDH, glyceraldehyde 3-phosphate dehydrogenase
- LPL, lipoprotein lipase
- Lipogenesis
- MDI, medium dependent interface
- MTT, 3-(4, 5-dimetylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
- ORO, Oil-red O
- PPARγ, peroxisome proliferator-activated receptor γ
- RIPD, radioimmunoprecipitation assay buffer
- SCD-1, stearoyl-CoA desaturase-1
- SREBP-1c, sterol regulatory element binding protein-1c
- TG, triglycerides
- aP2, fatty acid binding protein (aP2)
- p-AMPK, phosphorylated-AMPK
Collapse
Affiliation(s)
- Hae Jin Lee
- Department of Biotechnology, Chonnam National University, Yeosu 59626, Republic of Korea
| | - Bao Le
- Department of Biotechnology, Chonnam National University, Yeosu 59626, Republic of Korea
| | - Dong-Ryung Lee
- Nutrapharm Tech, Jungwon-gu, Seongnam, Gyeonggi 13201, Republic of Korea
| | - Bong-Keun Choi
- Nutrapharm Tech, Jungwon-gu, Seongnam, Gyeonggi 13201, Republic of Korea
| | - Seung Hwan Yang
- Department of Biotechnology, Chonnam National University, Yeosu 59626, Republic of Korea
| |
Collapse
|
8
|
Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB. Pre-heparin lipoprotein lipase mass as a potential mediator in the association between adiponectin and HDL-cholesterol in type 2 diabetes. J Clin Transl Endocrinol 2017; 7:7-11. [PMID: 29067244 PMCID: PMC5651302 DOI: 10.1016/j.jcte.2016.12.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 12/02/2016] [Accepted: 12/03/2016] [Indexed: 01/25/2023]
Abstract
AIM Lipoprotein lipase (LPL) is a major enzyme in lipid metabolism. Dyslipidemia, characterized by decreased high-density lipoprotein cholesterol (HDL-C), is prevalent in persons with type 2 diabetes mellitus (T2DM). The aim of this study was to determine whether pre-heparin LPL mass mediates the association between adiponectin and HDL-C in individuals with T2DM. METHODS Pre-heparin LPL mass was measured via an enzyme-linked immunosorbent assay, adiponectin by radioimmunoassay, and HDL-C was determined enzymatically. Participants' (n = 50) demographics, HbA1c, adiposity, homeostasis model assessment for insulin resistance (HOMA-IR), serum creatinine, and lipids were measured. Path analysis was utilized to test whether pre-heparin LPL mass is a mediator in the relationship between adiponectin and HDL-C. RESULTS All four criteria for mediation were satisfied in the path analysis. The indirect effect of adiponectin on HDL-C through pre-heparin LPL mass was significant, p = 0.001, whereas the direct effect of adiponectin on HDL-C was not significant, p = 0.074. These results remained consistent even after adjustments for age, gender, body mass index, HOMA-IR, and serum creatinine in the model. CONCLUSION The findings in this study suggest that pre-heparin LPL mass may mediate the association between adiponectin and HDL-C in T2DM. This relationship for measures of HDL-C functionality requires future investigation.
Collapse
Affiliation(s)
- Raelene E Maser
- Department of Medical Laboratory Sciences, University of Delaware, Newark, DE 19716, USA.,Diabetes and Metabolic Research Center, Christiana Care Health System, Newark, DE 19713, USA
| | - M James Lenhard
- Diabetes and Metabolic Research Center, Christiana Care Health System, Newark, DE 19713, USA.,Diabetes and Metabolic Diseases Center, Christiana Care Health System, Wilmington, DE 19801, USA
| | - Ryan T Pohlig
- Biostatistics Core Facility, University of Delaware, Newark, DE 19716, USA
| | - P Babu Balagopal
- Biomedical Research & Analysis Laboratory, Nemours Children's Specialty Care & Mayo Clinic College of Medicine, Jacksonville, FL 32207, USA
| |
Collapse
|
9
|
Cushing EM, Chi X, Sylvers KL, Shetty SK, Potthoff MJ, Davies BSJ. Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol Metab 2017; 6:809-18. [PMID: 28752045 DOI: 10.1016/j.molmet.2017.06.007] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 06/09/2017] [Accepted: 06/14/2017] [Indexed: 12/28/2022] Open
Abstract
Objective Angiopoietin-like 4 (ANGPTL4) is a fasting-induced inhibitor of lipoprotein lipase (LPL) and a regulator of plasma triglyceride metabolism. Here, we examined the kinetics of Angptl4 induction and tested the hypothesis that ANGPTL4 functions physiologically to reduce triglyceride delivery to adipose tissue during nutrient deprivation. Methods Gene expression, LPL activity, and triglyceride uptake were examined in fasted and fed wild-type and Angptl4−/− mice. Results Angptl4 was strongly induced early in fasting, and this induction was suppressed in mice with access to food during the light cycle. Fasted Angptl4−/− mice manifested increased LPL activity and triglyceride uptake in adipose tissue compared to wild-type mice. Conclusions Angptl4 is induced early in fasting to divert uptake of fatty acids and triglycerides away from adipose tissues. •Angptl4 is induced within the first few hours of fasting. •Angptl4 expression is driven by fasting rather than circadian rhythms. •Fasted Angptl4−/− mice have increased triglyceride uptake in adipose tissue. •Angptl4−/− mice also have increased LPL activity specifically in adipose tissue. •Data support a model where ANGPTL4 acts locally in adipose during fasting.
Collapse
|
10
|
Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Comput Struct Biotechnol J. 2017;15:359-365. [PMID: 28660014 PMCID: PMC5476973 DOI: 10.1016/j.csbj.2017.05.003] [Citation(s) in RCA: 94] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/15/2017] [Accepted: 05/22/2017] [Indexed: 12/31/2022] Open
Abstract
Apolipoprotein E (apoE), a 34 kDa glycoprotein, mediates hepatic and extrahepatic uptake of plasma lipoproteins and cholesterol efflux from lipid-laden macrophages. In humans, three structural different apoE isoforms occur, with subsequent functional changes and pathological consequences. Here, we review data supporting the involvement of apoE structural domains and isoforms in normal and altered lipid metabolism, cardiovascular and neurodegenerative diseases, as well as stress-related pathological states. Studies using truncated apoE forms provided valuable information regarding the regions and residues responsible for its properties. ApoE3 renders protection against cardiovascular diseases by maintaining lipid homeostasis, while apoE2 is associated with dysbetalipoproteinemia. ApoE4 is a recognized risk factor for Alzheimer's disease, although the exact mechanism of the disease initiation and progression is not entirely elucidated. ApoE is also implicated in infections with herpes simplex type-1, hepatitis C and human immunodeficiency viruses. Interacting with both viral and host molecules, apoE isoforms differently interfere with the viral life cycle. ApoE exerts anti-inflammatory effects, switching macrophage phenotype from the proinflammatory M1 to the anti-inflammatory M2, suppressing CD4+ and CD8+ lymphocytes, and reducing IL-2 production. The anti-oxidative properties of apoE are isoform-dependent, modulating the levels of various molecules (Nrf2 target genes, metallothioneins, paraoxonase). Mimetic peptides were designed to exploit apoE beneficial properties. The “structure correctors” which convert apoE4 into apoE3-like molecules have pharmacological potential. Despite no successful strategy is yet available for apoE-related disorders, several promising candidates deserve further improvement and exploitation.
Collapse
Key Words
- AD, Alzheimer's disease
- ApoE
- ApoE, Apolipoprotein E
- CVD, cardiovascular disease
- HCV, hepatitis C virus
- HDL, high-density lipoprotein
- HIV, human immunodeficiency virus
- HLP, phospholipid transfer protein
- HSPGs, heparan sulfate proteoglycans
- HSV-1, herpes simplex virus type-1
- Isoform
- LDL, low density lipoprotein
- LPG, lipoprotein glomerulopathy
- LPL, lipoprotein lipase
- Mimetic peptide
- NS5A, nonstructural protein 5A
- PLTP, type III hyperlipoproteinemia
- Structural domain
- TG, triglyceride
- Truncated molecule
- VLDL, very-low-density lipoprotein
Collapse
|
11
|
Wooten JS, Nick TN, Seija A, Poole KE, Stout KB. High-Fructose Intake Impairs the Hepatic Hypolipidemic Effects of a High-Fat Fish-Oil Diet in C57BL/6 Mice. J Clin Exp Hepatol 2016; 6:265-274. [PMID: 28003715 PMCID: PMC5157917 DOI: 10.1016/j.jceh.2016.09.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Accepted: 09/01/2016] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Overnutrition of saturated fats and fructose is one of the major factors for the development of nonalcoholic fatty liver disease. Because omega-3 polyunsaturated fatty acids (n-3fa) have established lipid lowering properties, we tested the hypothesis that n-3fa prevents high-fat and fructose-induced fatty liver disease in mice. METHODS Male C57BL/6J mice were randomly assigned to one of the following diet groups for 14 weeks: normal diet (ND), high-fat lard-based diet (HFD), HFD with fructose (HFD + Fru), high-fat fish-oil diet (FOD), or FOD + Fru. RESULTS Despite for the development of obesity and insulin resistance, FOD had 65.3% lower (P < 0.001) hepatic triglyceride levels than HFD + Fru, which was blunted to a 38.5% difference (P = 0.173) in FOD + Fru. The lower hepatic triglyceride levels were associated with a lower expression of lipogenic genes LXRα and FASN, as well as the expression of genes associated with fatty acid uptake and triglyceride synthesis, CD36 and SCD1, respectively. Conversely, the blunted hypotriglyceride effect of FOD + Fru was associated with a higher expression of CD36 and SCD1. CONCLUSIONS During overnutrition, a diet rich in n-3fa may prevent the severity of hepatic steatosis; however, when juxtaposed with a diet high in fructose, the deleterious effects of overnutrition blunted the hypolipidemic effects of n-3fa.
Collapse
Key Words
- ACC1, acetyl-CoA carboxylase-1
- CPT1a, carnitine palmitoyltransferase 1a
- ChREBP, carbohydrate response element binding protein
- FASN, fatty acid synthase
- FFA, free fatty acid
- LPL, lipoprotein lipase
- LXRα, liver-X-receptor
- MTTP, microsomal triglyceride transfer protein
- NAFLD, nonalcoholic fatty liver disease
- PPARα, peroxisome proliferator activated receptor α
- PPARγ, peroxisome proliferator activated receptor γ
- SCD1, stearoyl-CoA desaturase 1
- SREBP1c, sterol response element binding protein
- T2DM, type 2 diabetes mellitus
- TRL, triglyceride-rich lipoproteins
- VLDL, very low-density lipoprotein
- fructose
- lipid metabolism
- lipotoxicity
- n-3fa, omega-3 polyunsaturated fatty acids
- omega-3 polyunsaturated fatty acids
- overnutrition
Collapse
Affiliation(s)
- Joshua S. Wooten
- Address for correspondence: Joshua S. Wooten, Department of Applied Health, Southern Illinois University Edwardsville, Campus Box 1126, Edwardsville, IL 62026-1126, United States. Fax: +1 618 650 3719.Department of Applied Health, Southern Illinois University EdwardsvilleCampus Box 1126EdwardsvilleIL62026-1126United States
| | | | | | | | | |
Collapse
|
12
|
Kikuchi T, Orihara K, Oikawa F, Han SI, Kuba M, Okuda K, Satoh A, Osaki Y, Takeuchi Y, Aita Y, Matsuzaka T, Iwasaki H, Yatoh S, Sekiya M, Yahagi N, Suzuki H, Sone H, Nakagawa Y, Yamada N, Shimano H. Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression. Mol Metab 2016; 5:1092-1102. [PMID: 27818935 PMCID: PMC5081412 DOI: 10.1016/j.molmet.2016.09.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 09/06/2016] [Accepted: 09/10/2016] [Indexed: 12/12/2022] Open
Abstract
Objective The transcription factor cyclic AMP-responsive element-binding protein H (CREBH, encoded by Creb3l3) is highly expressed in the liver and small intestine. Hepatic CREBH contributes to glucose and triglyceride metabolism by regulating fibroblast growth factor 21 (Fgf21) expression. However, the intestinal CREBH function remains unknown. Methods To investigate the influence of intestinal CREBH on cholesterol metabolism, we compared plasma, bile, fecal, and tissue cholesterol levels between wild-type (WT) mice and mice overexpressing active human CREBH mainly in the small intestine (CREBH Tg mice) under different dietary conditions. Results Plasma cholesterol, hepatic lipid, and cholesterol crystal formation in the gallbladder were lower in CREBH Tg mice fed a lithogenic diet (LD) than in LD-fed WTs, while fecal cholesterol output was higher in the former. These results suggest that intestinal CREBH overexpression suppresses cholesterol absorption, leading to reduced plasma cholesterol, limited hepatic supply, and greater excretion. The expression of Niemann–Pick C1-like 1 (Npc1l1), a rate-limiting transporter mediating intestinal cholesterol absorption, was reduced in the small intestine of CREBH Tg mice. Adenosine triphosphate-binding cassette transporter A1 (Abca1), Abcg5/8, and scavenger receptor class B, member 1 (Srb1) expression levels were also reduced in CREBH Tg mice. Promoter assays revealed that CREBH directly regulates Npc1l1 expression. Conversely, CREBH null mice exhibited higher intestinal Npc1l1 expression, elevated plasma and hepatic cholesterol, and lower fecal output. Conclusion Intestinal CREBH regulates dietary cholesterol flow from the small intestine by controlling the expression of multiple intestinal transporters. We propose that intestinal CREBH could be a therapeutic target for hypercholesterolemia. Plasma cholesterol, hepatic lipid, and gallstones were lower in CREBH Tg mice. Expression of intestinal Npc1l1 was reduced in CREBH Tg mice. CREBH directly down-regulates mouse Npc1l1 promoter activity. Intestinal CREBH regulates dietary cholesterol flow from the small intestine.
Collapse
Key Words
- ABCG5/8, adenosine triphosphate-binding cassette transporter G5/G8
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- Abca1, ATP-binding cassette, sub-family A1
- Apoa4, apolipoprotein A-IV
- CREBH
- CREBH, cyclic AMP-responsive element-binding protein H
- Cholesterol
- Cpt1a, carnitine palmitoyltransferase 1a, liver
- Cyp7a1, cytochrome P450, family 7, subfamily a, polypeptide 1
- ER, endoplasmic reticulum
- FGF21, fibroblast growth factor 21
- FXR, Farnesoid X receptor
- Intestine
- LD, lithogenic diet
- LPL, lipoprotein lipase
- LXR, liver X receptor
- NEFA, non-esterified fatty acids
- NPC1L1, Nieman Pick C1-like 1
- Npc1l1
- PPARα, proliferator activated receptor alpha
- RCT, reverse cholesterol transport
- SREBP, sterol regulatory element-binding protein
- Shp, small heterodimer partner
- Srb1, scavenger receptor class B, member 1
- Srebf, sterol regulatory element-binding factor
- TG, triglyceride
- WT, wild type
Collapse
Affiliation(s)
- Takuya Kikuchi
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Kana Orihara
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Fusaka Oikawa
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Song-Iee Han
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Motoko Kuba
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Kanako Okuda
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Aoi Satoh
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Yoshinori Osaki
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Yoshinori Takeuchi
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Yuichi Aita
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Takashi Matsuzaka
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Hitoshi Iwasaki
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Shigeru Yatoh
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Motohiro Sekiya
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Naoya Yahagi
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Hiroaki Suzuki
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Hirohito Sone
- Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Niigata 951-8510, Japan
| | - Yoshimi Nakagawa
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
| | - Nobuhiro Yamada
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| | - Hitoshi Shimano
- Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; Life Science Center, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba 305-8577, Japan.
| |
Collapse
|
13
|
Scheithauer TP, Dallinga-Thie GM, de Vos WM, Nieuwdorp M, van Raalte DH. Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol Metab 2016; 5:759-70. [PMID: 27617199 PMCID: PMC5004227 DOI: 10.1016/j.molmet.2016.06.002] [Citation(s) in RCA: 121] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 06/01/2016] [Accepted: 06/06/2016] [Indexed: 02/08/2023] Open
Abstract
OBJECTIVE The twin pandemics of obesity and Type 2 diabetes (T2D) are a global challenge for health care systems. Changes in the environment, behavior, diet, and lifestyle during the last decades are considered the major causes. A Western diet, which is rich in saturated fat and simple sugars, may lead to changes in gut microbial composition and physiology, which have recently been linked to the development of metabolic diseases. METHODS We will discuss evidence that demonstrates the influence of the small and large intestinal microbiota on weight regulation and the development of insulin resistance, based on literature search. RESULTS Altered large intestinal microbial composition may promote obesity by increasing energy harvest through specialized gut microbes. In both large and small intestine, microbial alterations may increase gut permeability that facilitates the translocation of whole bacteria or endotoxic bacterial components into metabolic active tissues. Moreover, changed microbial communities may affect the production of satiety-inducing signals. Finally, bacterial metabolic products, such as short chain fatty acids (SCFAs) and their relative ratios, may be causal in disturbed immune and metabolic signaling, notably in the small intestine where the surface is large. The function of these organs (adipose tissue, brain, liver, muscle, pancreas) may be disturbed by the induction of low-grade inflammation, contributing to insulin resistance. CONCLUSIONS Interventions aimed to restoring gut microbial homeostasis, such as ingestion of specific fibers or therapeutic microbes, are promising strategies to reduce insulin resistance and the related metabolic abnormalities in obesity, metabolic syndrome, and type 2 diabetes. This article is part of a special issue on microbiota.
Collapse
Key Words
- 16s rRNA, 16S ribosomal RNA (30S small subunit of prokaryotic ribosomes)
- AMP, adenosine monophosphate
- AMPK, AMP-activated protein kinase
- AS160, Akt substrate of 160 kDa
- Angptl4, Angiopoietin-like 4
- CB1R, cannabinoid receptor type 1
- CCL2, Chemokine (C–C motif) ligand 2
- DIO, diet-induced obesity
- Diabetes
- GF, germ-free
- GLP, glucagon-like peptide
- Gpr, G-protein coupled receptor
- Gut microbiota
- HFD, high fat diet
- IL, interleukin
- IRS-1, insulin receptor substrate 1
- Insulin resistance
- JNK, C-Jun N-terminal kinase
- LBP, LPS-binding protein
- LPL, lipoprotein lipase
- LPS, lipopolysaccharide
- MCP-1, monocyte chemotactic protein 1
- NOD1, nucleotide-binding oligomerization domain-containing protein 1
- Obesity
- PKB, protein kinase B (also known as Akt)
- PYY, peptide YY (for tyrosine–tyrosine)
- RYGB, Roux-en-Y gastric bypass
- SCFA, short-chain fatty acid
- T2D, Type 2 diabetes mellitus
- TLR, toll-like receptor
- TNF-α, tumor necrosis factor alpha
- VLDL, very low density lipoprotein
- WHO, World Health Organization
- Weight regulation
- ZO, zonula occludens
Collapse
Affiliation(s)
- Torsten P.M. Scheithauer
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
- Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands
| | - Geesje M. Dallinga-Thie
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
| | - Willem M. de Vos
- WU Agrotechnology and Food Sciences, Wagening University, Wageningen, The Netherlands
| | - Max Nieuwdorp
- Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
- Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands
| | - Daniël H. van Raalte
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
- Institute for Cardiovascular Research (ICaR), VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
14
|
Tureck LV, Leite N, Souza RLR, da Silva Timossi L, Osiecki ACV, Osiecki R, Alle LF. ADIPOQ single nucleotide polymorphism: Association with adiponectin and lipoproteins levels restricted to men. Meta Gene 2015; 5:98-104. [PMID: 26137445 PMCID: PMC4484719 DOI: 10.1016/j.mgene.2015.06.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2015] [Revised: 05/22/2015] [Accepted: 06/08/2015] [Indexed: 12/12/2022] Open
Abstract
Adiponectin is an adipokine inversely correlated with obesity, which has beneficial effect on insulin resistance and lipid metabolism. Considering its potential as a therapeutic target in the metabolic disorder contexts, and in order to add knowledge in the area, our study evaluated the ADIPOQ 276G > T polymorphism effect on adiponectin levels, and on lipoproteins of clinical interest in a population sample composed of 211 healthy individuals. Significant effects were observed only among men: the carriers of heterozygous genotype (GT) showed high levels of adiponectin (p = 0.018), while the rare homozygous genotype (TT) gave its carriers a negative phenotype, represented by higher levels of low density lipoprotein cholesterol (LDL-C) (p = 0.004 and p = 0.005) and total cholesterol (TC) (p = 0.010 and p = 0.005) compared to carriers of other genotypes (GG and GT respectively), the independent effect of SNP on LDL-C and TC levels was confirmed by multiple regression analysis (p = 0.008 and p = 0.044). We found no evidence of correlation between circulating adiponectin levels and biochemical markers, which suggests, therefore, an SNP 276G > T independent effect on adiponectin levels and on lipoprotein metabolism in men enrolled in this study.
Collapse
Key Words
- 276G > T SNP
- ADIPOQ gene
- AMPK, adenosine monophosphate-activated protein kinase
- Adiponectin
- BMI, body mass index
- ELISA, enzyme-Linked Immunosorbent assay
- GWA study, genome-wide association study
- Gender effect
- HDL-C, high density lipoprotein cholesterol
- HL, hepatic lipase
- IDL, intermediate density lipoproteins
- LDL-C, low density lipoprotein cholesterol
- LDLR, LDL-C receptor
- LPL, lipoprotein lipase
- Lipid metabolism
- SNP, single-nucleotide polymorphism
- TC, total cholesterol
- TG, triglycerides
- VLDL, very low density lipoproteins
Collapse
Affiliation(s)
- Luciane Viater Tureck
- Polymorphism and Linkage Laboratory, Department of Genetics, Federal University of Paraná, Brazil
| | - Neiva Leite
- Department of Physical Education, Federal University of Paraná, Brazil
| | | | | | | | - Raul Osiecki
- Department of Physical Education, Federal University of Paraná, Brazil
| | - Lupe Furtado Alle
- Polymorphism and Linkage Laboratory, Department of Genetics, Federal University of Paraná, Brazil
| |
Collapse
|
15
|
Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 2015; 5:135-44. [PMID: 26579439 PMCID: PMC4629217 DOI: 10.1016/j.apsb.2015.01.004] [Citation(s) in RCA: 237] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2014] [Revised: 12/31/2014] [Accepted: 01/05/2015] [Indexed: 12/14/2022] Open
Abstract
Bile acids (BAs) are not only digestive surfactants but also important cell signaling molecules, which stimulate several signaling pathways to regulate some important biological processes. The bile-acid-activated nuclear receptor, farnesoid X receptor (FXR), plays a pivotal role in regulating bile acid, lipid and glucose homeostasis as well as in regulating the inflammatory responses, barrier function and prevention of bacterial translocation in the intestinal tract. As expected, FXR is involved in the pathophysiology of a wide range of diseases of gastrointestinal tract, including inflammatory bowel disease, colorectal cancer and type 2 diabetes. In this review, we discuss current knowledge of the roles of FXR in physiology of the digestive system and the related diseases. Better understanding of the roles of FXR in digestive system will accelerate the development of FXR ligands/modulators for the treatment of digestive system diseases.
Collapse
Key Words
- 6-ECDCA, 6α-ethyl-chenodeoxycholic acid
- AF2, activation domain
- ANGTPL3, angiopoietin-like protein 3
- AOM, azoxymethane
- AP-1, activator protein-1
- ASBT, apical sodium-dependent bile salt transporter
- Apo, apolipoprotein
- BAAT, bile acid-CoA amino acid N-acetyltransferase
- BACS, bile acid-CoA synthetase
- BAs, bile acids
- BMI, body mass index
- BSEP, bile salt export pump
- Bile acids
- CA, cholic acid
- CD, Crohn׳s disease
- CDCA, chenodeoxycholic acid
- CREB, cAMP regulatory element-binding protein
- CYP7A1, cholesterol 7α-hydroxylase
- Colorectal cancer
- DBD, DNA binding domain
- DCA, deoxycholic acid
- DSS, dextrane sodium sulfate
- ERK, extracellular signal-regulated kinase
- FABP6, fatty acid-binding protein subclass 6
- FFAs, free fatty acids
- FGF19, fibroblast growth factor 19
- FGFR4, fibroblast growth factor receptor 4
- FXR, farnesoid X receptor
- FXRE, farnesoid X receptor response element
- Farnesoid X receptor
- G6Pase, glucose-6-phosphatase
- GLP-1, glucagon-like peptide 1
- GLUT2, glucose transporter type 2
- GPBAR, G protein-coupled BA receptor
- GPCRs, G protein-coupled receptors
- GSK3, glycogen synthase kinase 3
- Gastrointestinal tract
- HDL-C, high density lipoprotein cholesterol
- HNF4α, hepatic nuclear factor 4α
- I-BABP, intestinal bile acid-binding protein
- IBD, inflammatory bowel disease
- IL-1, interleukin 1
- Inflammatory bowel disease
- KLF11, Krüppel-like factor 11
- KRAS, Kirsten rat sarcoma viral oncogene homolog
- LBD, ligand binding domain
- LCA, lithocholic acid
- LPL, lipoprotein lipase
- LRH-1, liver receptor homolog-1
- MCA, muricholicacid
- MRP2, multidrug resistance-associated protein 2
- NF-κB, nuclear factor-kappa B
- NOD, non-obese diabetic
- NRs, nuclear receptors
- OSTα, organic solute transporter alpha
- OSTβ, organic solute transporter beta
- PEPCK, phosphoenol pyruvate carboxykinase
- PGC-1α, peroxisome proliferators-activated receptor γ coactivator protein-1α
- SHP, small heterodimer partner
- SREBP-1c, sterol regulatory element-binding protein 1c
- STAT3, signal transducers and activators of transcription 3
- T2D, type 2 diabetes
- TLCA, taurolithocholic acid
- TNBS, trinitrobenzensulfonic acid
- TNFα, tumor necrosis factors α
- Type 2 diabetes
- UC, ulcerative colitis
- UDCA, ursodeoxycholic acid
- VSG, vertical sleeve gastrectomy
- db/db, diabetic mice
Collapse
|
16
|
Kliewer KL, Ke JY, Tian M, Cole RM, Andridge RR, Belury MA. Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biol Ther 2014; 16:886-97. [PMID: 25457061 DOI: 10.4161/15384047.2014.987075] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Cancer cachexia is a progressive metabolic disorder that results in depletion of adipose tissue and skeletal muscle. A growing body of literature suggests that maintaining adipose tissue mass in cachexia may improve quality-of-life and survival outcomes. Studies of lipid metabolism in cachexia, however, have generally focused on later stages of the disorder when severe loss of adipose tissue has already occurred. Here, we investigated lipid metabolism in adipose, liver and muscle tissues during early stage cachexia - before severe fat loss - in the colon-26 murine model of cachexia. White adipose tissue mass in cachectic mice was moderately reduced (34-42%) and weight loss was less than 10% of initial body weight in this study of early cachexia. In white adipose depots of cachectic mice, we found evidence of enhanced protein kinase A - activated lipolysis which coincided with elevated total energy expenditure and increased expression of markers of brown (but not white) adipose tissue thermogenesis and the acute phase response. Total lipids in liver and muscle were unchanged in early cachexia while markers of fatty oxidation were increased. Many of these initial metabolic responses contrast with reports of lipid metabolism in later stages of cachexia. Our observations suggest intervention studies to preserve fat mass in cachexia should be tailored to the stage of cachexia. Our observations also highlight a need for studies that delineate the contribution of cachexia stage and animal model to altered lipid metabolism in cancer cachexia and identify those that most closely mimic the human condition.
Collapse
Key Words
- ACOX, acyl CoA oxidase
- ATGL, adipose triglyceride lipase
- COX, cytochrome c oxidase subunits
- CPT, carnitine palmitoyltransferase
- CRP, C-reactive protein
- DIO, iodothyronine deiodinase
- GYK, glycerokinase
- H&E, hematoxylin and eosin
- HSL, hormone sensitive lipase
- LPL, lipoprotein lipase
- MuRF, muscle ring finger protein
- PGC, peroxisome proliferator activated receptor gamma coactivator
- PKA, protein kinase A
- PPAR, peroxisome proliferator activated receptor
- PRDM, PR domain zinc finger protein
- RER, respiratory exchange ratio.
- TEE, total energy expenditure
- UCP, uncoupling protein
- colon-26 adenocarcinoma
- eWAT, epididymal white adipose tissue
- early cachexia
- energy expenditure
- iBAT, interscapular brown adipose tissue
- iWAT, inguinal white adipose tissue
- lipid metabolism
- lipolysis
- thermogenesis
Collapse
Affiliation(s)
- Kara L Kliewer
- a Department of Human Sciences ; College of Education and Human Ecology ; The Ohio State University ; Columbus , OH USA
| | | | | | | | | | | |
Collapse
|
17
|
Vienberg SG, Kleinridders A, Suzuki R, Kahn CR. Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity. Mol Metab 2015; 4:144-50. [PMID: 25685701 DOI: 10.1016/j.molmet.2014.11.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Revised: 11/03/2014] [Accepted: 11/05/2014] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE Lipoprotein lipase (LPL) is a key regulator of circulating triglyceride rich lipoprotein hydrolysis. In brain LPL regulates appetite and energy expenditure. Angiopoietin-like 4 (Angptl4) is a secreted protein that inhibits LPL activity and, thereby, triglyceride metabolism, but the impact of Angptl4 on central lipid metabolism is unknown. METHODS We induced type 1 diabetes by streptozotocin (STZ) in whole-body Angptl4 knockout mice (Angptl4(-/-) ) and their wildtype littermates to study the role of Angptl4 in central lipid metabolism. RESULTS In type 1 (streptozotocin, STZ) and type 2 (ob/ob) diabetic mice, there is a ~2-fold increase of Angptl4 in the hypothalamus and skeletal muscle. Intracerebroventricular insulin injection into STZ mice at levels which have no effect on plasma glucose restores Angptl4 expression in hypothalamus. Isolation of cells from the brain reveals that Angptl4 is produced in glia, whereas LPL is present in both glia and neurons. Consistent with the in vivo experiment, in vitro insulin treatment of glial cells causes a 50% reduction of Angptl4 and significantly increases LPL activity with no change in LPL expression. In Angptl4(-/-) mice, LPL activity in skeletal muscle is increased 3-fold, and this is further increased by STZ-induced diabetes. By contrast, Angptl4(-/-) mice show no significant difference in LPL activity in hypothalamus or brain independent of diabetic and nutritional status. CONCLUSION Thus, Angptl4 in brain is produced in glia and regulated by insulin. However, in contrast to the periphery, central Angptl4 does not regulate LPL activity, but appears to participate in the metabolic crosstalk between glia and neurons.
Collapse
Key Words
- ARC, arcuate nucleus
- AgRP, agouti-related protein
- Angptl4
- Angptl4, angiopoietin-like 4
- CART, cocaine-and-amphetamine-regulated transcript
- CNS, central nervous system
- FFA, free fatty acid
- LPL, lipoprotein lipase
- Lipid metabolism
- Lipoprotein lipase
- NPY, neuropeptide-Y
- POMC, pro-opiomelanocortin
- STZ, streptozotocin
- TG, triglyceride
Collapse
|
18
|
Kim JH, Meyers MS, Khuder SS, Abdallah SL, Muturi HT, Russo L, Tate CR, Hevener AL, Najjar SM, Leloup C, Mauvais-Jarvis F. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol Metab 2014; 3:177-90. [PMID: 24634829 DOI: 10.1016/j.molmet.2013.12.009] [Citation(s) in RCA: 86] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 12/20/2013] [Accepted: 12/21/2013] [Indexed: 12/11/2022] Open
Abstract
Pairing the selective estrogen receptor modulator bazedoxifene (BZA) with estrogen as a tissue-selective estrogen complex (TSEC) is a novel menopausal therapy. We investigated estrogen, BZA and TSEC effects in preventing diabetisity in ovariectomized mice during high-fat feeding. Estrogen, BZA or TSEC prevented fat accumulation in adipose tissue, liver and skeletal muscle, and improved insulin resistance and glucose intolerance without stimulating uterine growth. Estrogen, BZA and TSEC improved energy homeostasis by increasing lipid oxidation and energy expenditure, and promoted insulin action by enhancing insulin-stimulated glucose disposal and suppressing hepatic glucose production. While estrogen improved metabolic homeostasis, at least partially, by increasing hepatic production of FGF21, BZA increased hepatic expression of Sirtuin1, PPARα and AMPK activity. The metabolic benefits of BZA were lost in estrogen receptor-α deficient mice. Thus, BZA alone or in TSEC produces metabolic signals of fasting and caloric restriction and improves energy and glucose homeostasis in female mice.
Collapse
Key Words
- AMPKα, AMP-activated protein kinase α
- AUC, area-under the curve
- Akt, protein kinase B
- BAT, brown adipose tissue
- BZA, bazedoxifene
- Bazedoxifene
- CE, conjugated equine estrogens
- E2, 17β-estradiol
- ER, estrogen receptor
- FAS, fatty acid synthase
- FGF21, fibroblast growth factor 21
- GIR, glucose infusion rate
- H&E, hematoxylin and eosin
- HFD, high-fat diet
- HGP, hepatic glucose production
- ITT, insulin tolerance test
- Insulin resistance
- LPL, lipoprotein lipase
- Lcn2, lipocalin 2
- Menopause
- Metabolic syndrome
- NAFLD, non-alcoholic fatty liver disease
- OGTT, oral glucose tolerance test
- OVX, ovariectomy
- PTT, pyruvate tolerance test
- RBP4, retinol binding protein 4
- RER, respiratory exchange ratio
- Rd, rate of whole-body glucose disappearance
- SERM, selective estrogen receptor modulator
- TBARS, thiobarbituric acid reactive substances
- TG, triacylglycerol
- TSEC, tissue-selective estrogen complex
- Tissue-selective estrogen complexes
- Type 2 diabetes
- UCPs, uncoupling proteins
- VO2, oxygen consumption
- WAT, white adipose tissue.
Collapse
Affiliation(s)
- Jun Ho Kim
- Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Matthew S Meyers
- Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Saja S Khuder
- Center for Diabetes and Endocrine Research, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
| | - Simon L Abdallah
- Center for Diabetes and Endocrine Research, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
| | - Harrison T Muturi
- Center for Diabetes and Endocrine Research, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
| | - Lucia Russo
- Center for Diabetes and Endocrine Research, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
| | - Chandra R Tate
- Department of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA 70112, USA
| | - Andrea L Hevener
- Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Sonia M Najjar
- Center for Diabetes and Endocrine Research, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA
| | - Corinne Leloup
- Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Franck Mauvais-Jarvis
- Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Department of Medicine, Division of Endocrinology and Metabolism, Tulane University Health Sciences Center, School of Medicine, New Orleans, LA 70112, USA
| |
Collapse
|
19
|
Picard A, Rouch C, Kassis N, Moullé VS, Croizier S, Denis RG, Castel J, Coant N, Davis K, Clegg DJ, Benoit SC, Prévot V, Bouret S, Luquet S, Le Stunff H, Cruciani-Guglielmacci C, Magnan C. Hippocampal lipoprotein lipase regulates energy balance in rodents. Mol Metab 2013; 3:167-76. [PMID: 24634821 DOI: 10.1016/j.molmet.2013.11.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Revised: 11/07/2013] [Accepted: 11/13/2013] [Indexed: 01/22/2023] Open
Abstract
Brain lipid sensing is necessary to regulate energy balance. Lipoprotein lipase (LPL) may play a role in this process. We tested if hippocampal LPL regulated energy homeostasis in rodents by specifically attenuating LPL activity in the hippocampus of rats and mice, either by infusing a pharmacological inhibitor (tyloxapol), or using a genetic approach (adeno-associated virus expressing Cre-GFP injected into Lpl (lox/lox) mice). Decreased LPL activity by either method led to increased body weight gain due to decreased locomotor activity and energy expenditure, concomitant with increased parasympathetic tone (unchanged food intake). Decreased LPL activity in both models was associated with increased de novo ceramide synthesis and neurogenesis in the hippocampus, while intrahippocampal infusion of de novo ceramide synthesis inhibitor myriocin completely prevented body weight gain. We conclude that hippocampal lipid sensing might represent a core mechanism for energy homeostasis regulation through de novo ceramide synthesis.
Collapse
Key Words
- AAV, adeno-associated virus
- ANS, autonomic nervous system
- CERS, ceramide synthase
- CNS, central nervous system
- Ceramides
- Energy expenditure
- GFP, green fluorescent protein
- LPL, lipoprotein lipase
- Lipid sensing
- Obesity
- Parasympathetic nervous system
- RQ, respiratory quotient
- SMPD1, acid sphingomyelin phosphodiesterase 1
- SPHK1, sphingosine kinase 1
- SPT, serine palmitoyltransferase
- TG, triglycerides
Collapse
Affiliation(s)
- Alexandre Picard
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| | - Claude Rouch
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France ; Centre National de la Recherche Scientifique-CNRS EAC 4413, F-75205 Paris, France
| | - Nadim Kassis
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France ; Centre National de la Recherche Scientifique-CNRS EAC 4413, F-75205 Paris, France
| | - Valentine S Moullé
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| | - Sophie Croizier
- Jean-Pierre Aubert Research Center, Development and Plasticity of the Postnatal Brain, INSERM U837, 59045 Lille Cedex, France
| | - Raphaël G Denis
- Jean-Pierre Aubert Research Center, Development and Plasticity of the Postnatal Brain, INSERM U837, 59045 Lille Cedex, France
| | - Julien Castel
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France ; Centre National de la Recherche Scientifique-CNRS EAC 4413, F-75205 Paris, France
| | - Nicolas Coant
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| | - Kathryn Davis
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Deborah J Clegg
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Stephen C Benoit
- Department of Psychiatry, University of Cincinnati, Cincinnati, OH, USA
| | - Vincent Prévot
- Jean-Pierre Aubert Research Center, Development and Plasticity of the Postnatal Brain, INSERM U837, 59045 Lille Cedex, France
| | - Sébastien Bouret
- Jean-Pierre Aubert Research Center, Development and Plasticity of the Postnatal Brain, INSERM U837, 59045 Lille Cedex, France ; The Saban Research Institute, Neuroscience Program, Children's Hospital Los Angeles, University of Southern California, Los Angeles, USA
| | - Serge Luquet
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France ; Centre National de la Recherche Scientifique-CNRS EAC 4413, F-75205 Paris, France
| | - Hervé Le Stunff
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| | - Céline Cruciani-Guglielmacci
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| | - Christophe Magnan
- Université Paris Diderot, Sorbonne Paris Cité, BFA, EAC 4413 CNRS, Case courrier 7126, 4, rue Marie Andrée Lagroua Weill-Hallé, F-75205 Paris Cedex 13, France
| |
Collapse
|